Human respiratory syncytial virus regulates the expression of interferon-stimulated genes through modulation of fibrillarin.

José Manuel Ulloa-Aguilar, Victor Javier Cruz-Holguin, Yazmín Rocío Benítez-Zeferino, Edgar Rodrigo Guzmán-Bautista, Julio García-Cordero, Luis Adrián De Jesús-González, Julio Angel Vázquez-Martínez, Edgar Ricardo Vázquez-Martínez, Luis Herrera-Moro Huitron, Alfredo Mosqueda-Gracida, Monica Viveros-Rogel, Moises Vergara-Mendoza, Roxana Uri Miranda-Labra, Moises León-Juárez

Journal: Frontiers in cellular and infection microbiology 2026;16():1706028

PMID: 42064218

Abstract

INTRODUCTION

Human respiratory syncytial virus (RSV) is one of the main viral agents associated with the development of acute respiratory infections (ARIs), particularly during infancy and early childhood. RSV vaccine have recently been approved, however, are currently limited to older adults and pregnant women, with no approval for young children. In the absence of broadly effective and accessible preventive or therapeutic options for this vulnerable population, understanding the biology of RSV represents a critical alternative strategy. While several viral proteins have been reported to regulate the expression of interferon-stimulated genes (ISGs) to evade the host antiviral immune response, recent studies have shown that some viruses can also recruit host cellular proteins to facilitate their replication or modulate antiviral pathways. In this context, the nucleolus, and its resident proteins, such as fibrillarin (FBL), have been suggested to play a role in the regulation of inflammatory responses and in the activation of genes involved in early antiviral defense mechanisms.

METHODS

To analyze FBL expression under viral infection conditions, immunofluorescence assays (IFA) and Western blot (WB) analyses were performed. The effects of FBL depletion were evaluated using WB, IFA, RT-qPCR, and lytic plaque assays. Three experimental conditions were established: uninfected A549 cells (mock), RSV-infected cells, and RSV-infected cells with FBL knockdown. To determine the relationship between FBL and interferon-stimulated gene (ISG) expression, RT-qPCR assays were performed to quantify the expression levels of selected ISGs, including OAS1, OAS2, IFIT3, PKR, and RIG-I. Additionally, FBL-knockdown cells were transfected with a GFP-FBL construct to restore FBL expression, and the recovery of RSV infection was evaluated by IFA, RT-qPCR, and plaque-forming unit (PFU) assays. Moreover, the downregulation of ISG expression in cells with restored GFP-FBL was assessed by RT-qPCR. Finally, p53 knockdown assays were performed to evaluate changes in FBL expression and the reduction of RSV infection, as determined by WB.

RESULTS

RSV infection was found to induce FBL expression at early stages of infection in A549 cells. Additionally, our data suggest that FBL suppresses the expression of interferon-stimulated genes (ISGs). Conversely, silencing of FBL significantly reduced RSV infection. Importantly, this reduction in viral replication was associated with increased ISG expression in FBL-deficient A549 cells upon RSV infection. Furthermore, exogenous expression of FBL in FBL-knockdown cells restored RSV infection and led to a concomitant reduction in ISG expression following the recovery of FBL protein levels. Finally, p53-knockdown cells reduced viral protein M2-1 levels without affecting FBL expression, pointing to the involvement of other regulatory mechanism controlling FBL during RSV infection.

CONCLUSION

Our data show that RSV infection promotes the expression of the FBL protein, creating an environment devoid of early antiviral response mediators such as ISGS.

Copyright © 2026 Ulloa-Aguilar, Cruz-Holguin, Benítez-Zeferino, Guzmán-Bautista, García-Cordero, De Jesús-González, Vázquez-Martínez, Vázquez-Martínez, Herrera-Moro Huitron, Mosqueda-Gracida, Viveros-Rogel, Vergara-Mendoza, Miranda-Labra and León-Juárez.

Address: Laboratorio de Virología Perinatal y Diseño Molecular de Antigenos y Biomarcadores, Departamento de Inmunobioquimica, Instituto Nacional de Perinatología, Mexico City, Mexico.; Posgrado en Biología Experimental, Divsión de Ciencias biologicas y de la Salud (DCBS), Universidad Autónoma Metropolitana- Iztapalapa, Mexico City, Mexico.; Laboratorio de Virología Perinatal y Diseño Molecular de Antigenos y Biomarcadores, Departamento de Inmunobioquimica, Instituto Nacional de Perinatología, Mexico City, Mexico.; Instituto de Investigación Sobre la Salud Pública, Universidad de la Sierra Sur, Miahuatlan de Porfirio Díaz, Oaxaca, Mexico.; Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Mexico City, Mexico.; Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas, Mexico.; Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, United States.; Unidad de Investigación en Reproducción Humana, Instituto Nacional de Perinatología - Facultad de Química, Universidad Nacional Autónoma de México, Mexico City, Mexico.; Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.; Departamento de Ciencias de la Salud, Universidad Autónoma Metropolitana, Unidad Iztapalapa, Mexico City, Mexico.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.